Janusz K.
- Country
- Poland
- Department
- Oddzial Kliniczny Onkologii i Immunoonkologii z Osrodkiem Dziennym Terapii Onkologicznej
Research Overview
- Phase III Randomized Study of Durvalumab, Tremelimumab, and Chemotherapy in Unresectable Locally Advanced or Metastatic Urothelial Carcinoma
- A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
- A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
Data & Insights
Has run more than one trial at 13 of 97 partner sites.
Specializations
Hematologic malignancies
Clinical research activity includes acute myeloid leukemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and classical Hodgkin lymphoma, with additional involvement in broader B-cell malignancies and non-Hodgkin lymphoma.
- Multiple myeloma
- Myelodysplastic syndromes
- Acute lymphoblastic leukemia
- Myelofibrosis
The therapeutic focus also extends to transfusion-dependent anemia and autoimmune hemolytic anemia, reflecting interest in supportive and disease-modifying hematology.
Solid tumors of the digestive system
Research involvement covers hepatocellular carcinoma, biliary tract cancer, gastric cancer, and gastroesophageal junction adenocarcinoma, with additional work in esophageal squamous cell carcinoma and head and neck squamous cell carcinoma.
- Colorectal cancer
- Endometrial cancer
- Ovarian cancer
- Hepatocellular carcinoma
Therapeutic interests include biomarker-defined gastrointestinal oncology, with attention to FGFR2b overexpression, BRCA mutation, and HER2-positive disease.
Thoracic and genitourinary oncology
Clinical trial activity includes non-small cell lung cancer, small cell lung cancer, and unresectable esophageal cancer, alongside urothelial cancer and muscle-invasive bladder cancer.
- Metastatic urothelial cancer
- Prostate cancer
- Upper tract urothelial cancer
- Bladder carcinoma
The portfolio also includes metastatic hormone-sensitive prostate cancer and PTEN-deficient disease, indicating interest in targeted treatment strategies across advanced genitourinary malignancies.
Immuno-oncology and targeted therapy
Investigational activity spans immune checkpoint inhibitors, bispecific antibodies, antibody-drug conjugates, BTK inhibitors, and other targeted agents across multiple tumor types.
- PD-L1–directed therapy
- HER3-targeted treatment
- CD20-positive malignancies
- FLT3-mutated AML
Research interests include molecularly selected cancers and treatment-resistant disease, with emphasis on therapeutic innovation in refractory settings.
Hematologic supportive care and inflammatory disorders
Additional clinical interest is seen in hypogammaglobulinemia associated with B-cell malignancies, warm autoimmune hemolytic anemia, and cancer cachexia.
- Acute decompensated heart failure
- Thalassemia
- Red blood cell transfusion dependence
- Infection prevention in hematologic disease
The therapeutic landscape also includes cardiometabolic support in hospitalized heart failure and management of chronic anemia-related complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.